NCT04069143 is a Phase 1 clinical trial of 18F-BMS-986327 in Healthy Participants, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT04069143?

NCT04069143 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT04069143?

Interventions in NCT04069143: 18F-BMS-986327.

What condition does NCT04069143 study?

NCT04069143 studies Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF).

Is NCT04069143 still recruiting?

NCT04069143 is currently completed. Last updated 7 March 2023.

Last reviewed 2023-03-07 · How we verify

NCT04069143

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Completed Phase 1 Last updated 7 March 2023

What this trial tests

Phase 1 trial testing 18F-BMS-986327 in Healthy Participants in 14 participants. Completed in 12 July 2022.

Timeline

1 October 2019

Primary endpoint
12 July 2022

12 July 2022

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	14
Start date	1 October 2019
Primary completion	12 July 2022
Estimated completion	12 July 2022
Sites	1 location across United States

Drugs / interventions tested

18F-BMS-986327

Conditions studied

Healthy Participants — all drugs for Healthy Participants →
Idiopathic Pulmonary Fibrosis (IPF) — all drugs for Idiopathic Pulmonary Fibrosis (IPF) →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Healthy Participants or Idiopathic Pulmonary Fibrosis (IPF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with idiopathic pulmonary fibrosis (IPF).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Myofibroblasts in Physiological and Pathological Tissue Repair.
Schuster R, Younesi F, Ezzo M, Hinz B. · · 2023 · cited 148× · PMID 36123034 · DOI 10.1101/cshperspect.a041231
Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.
Suryadevara V, Ramchandran R, Kamp DW, Natarajan V. · · 2020 · cited 111× · PMID 32549377 · DOI 10.3390/ijms21124257
Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
Lin YH, Lin YC, Chen CC. · · 2021 · cited 37× · PMID 34209775 · DOI 10.3390/cells10071629
Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases.
Jiang S, Yang H, Li M. · · 2023 · cited 23× · PMID 37569902 · DOI 10.3390/ijms241512524

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04069143 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 7 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04069143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing